Information Provided By: 
Fly News Breaks for November 28, 2017
BCRX
Nov 28, 2017 | 08:14 EDT
JMP Securities analyst Liisa Bayko said her survey of allergists found them to be "bullish" on BioCryst's lead asset, BCX7353, even in the context of other highly effective hereditary angioedema treatment options. This physician enthusiasm is disconnected from BioCryst's valuation, contends Bayko, who reiterates her Outperform rating and $12 price target on the stock.
News For BCRX From the Last 2 Days
There are no results for your query BCRX
